Top

Published in:

Open Access 22-03-2024 | Arterial Hypertension | Review Article

Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications

Authors: Maria Eugenia Novara, Enrica Di Martino, Brandon Stephens, Mary Nayrouz, Patrizio Vitulo, Anna Carollo, Alessio Provenzani

Published in: Drugs in R&D | Issue 1/2024

Abstract

Pulmonary arterial hypertension is characterized by elevated blood pressure and pathological changes in the pulmonary arterioles, leading to the development of right-heart failure and potentially fatal outcomes if left untreated. This review aims to provide an overview of novel drugs or formulations and new drug indications for pulmonary arterial hypertension that are currently in phases II–III of randomized controlled trials, and describe the rationale for the use of these targeted therapies, as well as their efficacy, safety profile, and impact on quality of life and survival. The literature research was conducted using data from ClinicalTrials.gov for the period between 1 January 2016 up to 31 December 2022. The population of interest includes individuals aged ≥ 18 years who have been diagnosed with pulmonary arterial hypertension. The review selection criteria included trials with recruiting, enrolling by invitation, active, terminated or completed status in 2022 and 2023. A total of 24 studies were selected for evaluation based on the inclusion and exclusion criteria. This review summarizes the updated information from randomized clinical trials involving novel therapies for pulmonary arterial hypertension. However, larger clinical trials are required to validate their clinical safety and effects. In the future, clinicians should choose therapies based on the patient's individual situation and requirements when developing treatment strategies.

Thenappan T, Prins K. Who Group I Pulmonary Hypertension: epidemiology and pathophysiology. Cardiol Clin. 2016;34(3):363–74. https://doi.org/10.1016/J.Ccl.2016.04.001.CrossRefPubMedPubMedCentral

Thenappan T, Ormiston M, Ryan J, Archer S. pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018. https://doi.org/10.1136/Bmj.J5492.CrossRefPubMedPubMedCentral

Orphanet. Procedural document on the orphanet nomenclature and classification of rare diseases. Orphanet J Rare Dis. 2020;02:1–7.

Task A, Members F, Humbert M, Germany Mmh, Berger Rmf, Denmark Jc, Germany Em, Germany Bn, Germany Kmo, Kingdom Jpu, Quint Jk, Kingdom U, France Gs, France Os, Toshner M, Kingdom U. 2022 Esc/Ers Guidelines For The Diagnosis And Treatment Of Pulmonary Hypertension Developed By The Task Force For The Diagnosis And Treatment Of (Esc) And The European Respiratory Society (ERS). Endorsed By The International Society For Heart And Lu. Eur Heart J. 2022;43(38):3618–3731. https://doi.org/10.1093/Eurheartj/Ehac237(Erratum In: Eur Heart J. 2023 Feb 23).

Zelt JGE, Sugarman J, Weatherald J, Partridge ACR, Liang JC, Swiston J, Brunner N, Chandy G, Stewart DJ, Contreras-Dominguez V, Thakrar M, Helmersen D, Varughese R, Hirani N, Umar F, Dunne R, Doyle-Cox C, Foxall J, Mielniczuk L. Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era. Eur Respir J. 2022;59(6):2101552. https://doi.org/10.1183/13993003.01552-2021.CrossRefPubMedPubMedCentral

Evans JDW, Girerd B, Montani D, Wang X, Galiè N, Austin E, Elliott G, Asano K, Eichstaedt C, Hinderhofer K, Wolf M, Rosenzweig E, Chung W, Soubrier F, Simonneau G, Sitbon O, Gräf S, Kaptoge S, Angelantonio E, Humbert M, Morrell N, Pierre U. Bmpr2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016;4(2):129–37. https://doi.org/10.1016/S2213-2600(15)00544-5.CrossRefPubMedPubMedCentral

Condon DF, Agarwal S, Chakraborty A, Auer N, Vazquez R, Patel H, Zamanian RT, de Jesus Perez VA. Novel mechanisms targeted by drug trials in pulmonary arterial hypertension. Chest. 2022;161(4):1060–72. https://doi.org/10.1016/j.chest.2021.10.010.CrossRefPubMed

Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):13S-24S. https://doi.org/10.1016/j.jacc.2004.02.029.CrossRefPubMed

Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70–5.PubMedCrossRef

10.

Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159(6):1925–32.PubMedCrossRef

11.

Klinger JR, Abman SH, Gladwin MT. Nitric oxide defciency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188(6):639–46.PubMedCrossRef

12.

Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative efects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172(1):105–13.PubMedCrossRef

13.

Humbert M, Sitbon O, Simonneau G. Treatment of pulmo-nary arterial hypertension. N Engl J Med. 2004;351(14):1425–36.

14.

Izbicki G, Rosengarten D, Picard E. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2006;354(10):1091–3.

15.

Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafl citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.PubMedCrossRef

16.

McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46:405–13.PubMedCrossRef

17.

Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31:1124–31.PubMedCrossRef

18.

Vizza CD, Jansa P, Teal S, et al. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovasc Disord. 2017;17:239.PubMedPubMedCentralCrossRef

19.

Ling-Yun AI, Chen GUO, Yan DING, et al. CliIIical observation of Bosentan combined with Sildenafil in the treatment of congenital heart disease with severe pulmonary arterial hypertension. China Mod Med. 2016;23:112–4.

20.

Jian-Yong ZHU, Yu-Qin ZENG, Qing HU, et al. Clinical effect of sildenafil combined with Bosentan in treatment of connective tissue disease associated moderate-severe pulmonary arterial hypertension. Chin J Respir Crit Care Med. 2018;17:369–72.

21.

Bermejo J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, Castano M, Segovia-Cubero J, Sildenafil for Improving Outcomes after VAlvular Correction (SIOVAC) investigators et al. (2018) Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 39:1255–64.

22.

White RJ, Vonk-Noordegraaf A, Rosenkranz S, et al. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Respir Res. 2019;20:208.PubMedPubMedCentralCrossRef

23.

Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834–44.PubMedCrossRef

24.

Kuwana M, Blair C, Takahashi T, et al. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intentionto-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis. 2020;79:626–34.PubMedCrossRef

25.

Jian-zhou GUO, Yan-yan MA, Zhi-wei WANG. Clinical effect and changes of cardiac function in patients with pulmonary hypertension after operation of congenital heart disease applicating tadalafil combined with Bosentan. South China J Cardiovasc Dis. 2018;24:40.

26.

De-Zhen Z, An-Meng WEI. Effect of Bosentan combined with tadalafil on activity endurance and cardiac function in patients with pulmonary hypertension. Chin J Clinicians. 2020;48:566–9.

27.

Zhuang Y, Jiang B, Gao H, Zhao W. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertens Res. 2014;37:507–12.PubMedCrossRef

28.

Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30:632–43.

29.

Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014;145:810–7.PubMedCrossRef

30.

Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.PubMedCrossRef

31.

Gali e N, Humbert M, Vachiery J-L, Vizza C, Kneussl M, Manes A, Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496–502.

32.

Badesch D, Bodin F, Channick R, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Curr Ther Res. 2002;63:227–46.CrossRef

33.

Galie N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–100.PubMedCrossRef

34.

Ni AI, Wa ER. To investigate the clinical effect of Bosentan in the treatment of patients with congenital heart disease complicated with pulmonary hypertension. China Health Care Nutr. 2018;28:187–96.

35.

McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257–63.PubMedCrossRef

36.

Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28:691–4.PubMedCrossRef

37.

Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P, Gibbs JS. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171(11):1292–7. https://doi.org/10.1164/rccm.200410-1411OC.CrossRefPubMed

38.

Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Circulation. 2008;117:3010–9.PubMedCrossRef

39.

Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, MAESTRO Study Investigators, et al. Evaluation of macitentan in patients with eisenmenger syndrome. Circulation. 2019;139:51–63.

40.

Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–18.PubMedCrossRef

41.

Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019;7:594–604.PubMedCrossRef

42.

Jansa P, Pulido T. Macitentan in pulmonary arterial hypertension: a focus on combination therapy in the seraphin trial. Am J Cardiovasc Drugs. 2018;18:1–11.PubMedCrossRef

43.

Galie N, Muller K, Scalise A-V, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45:1314–22.PubMedCrossRef

44.

Rubin LJ, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015;45:1303–13.PubMedCrossRef

45.

Rosenkranz S, Ghofrani H-A, Beghetti M, et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015;101:1792–9.PubMedCrossRef

46.

Humbert M, Coghlan JG, Ghofrani H-A, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2017;76:422–6.PubMedCrossRef

47.

Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–4.PubMedCrossRef

48.

Badesch DB. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;6:425–34.CrossRef

49.

Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301.PubMedCrossRef

50.

Barst RJ. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart. 1997;4:299–301.CrossRef

51.

Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353–9.PubMedCrossRef

52.

McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915–22.PubMedCrossRef

53.

Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624–33. https://doi.org/10.1161/CIRCULATIONAHA.112.124388.CrossRefPubMed

54.

Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, TRUST Study Group, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29:137–49.

55.

Ronald JO. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;2:420–7.

56.

Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142:1383–90.PubMedCrossRef

57.

Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40:874–80.PubMedCrossRef

58.

Coghlan JG, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs. 2018;18:37–47.PubMedPubMedCentralCrossRef

59.

Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–33.PubMedCrossRef

60.

Goumans MJ, Liu Z, Ten DP. TGF-β signaling in vascular biology and dysfunction. Cell Res. 2009;19:116–27.PubMedCrossRef

61.

Kurakula K, Goumans MJ, Ten DP. Regulatory RNAs controlling vascular (dys)function by affecting TGF-β family signalling. EXCLI J. 2015;14:832–50.PubMedPubMedCentral

62.

Atkinson C, Stewart S, Upton PD, Machado RD, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105:1672–8.PubMedCrossRef

63.

Chen N-Y, Collum SD, Luo F, Weng T, Le T-T, Hernandez AM, Philip K, Molina JG, Garcia-Morales LJ, Cao Y, et al. Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2016;311:L238–54.PubMedPubMedCentralCrossRef

64.

Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Investig. 2012;122:4306–13.PubMedPubMedCentralCrossRef

65.

Yang X, Long L, Reynolds P, Morrell N. Expression of mutant Bmpr-Ii in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells. Pulm Circ 2011;1(1):103–10. https://doi.org/10.4103/2045-8932.78100.

66.

Ormiston M, Upton P, Li W, Morrell N. The promise of recombinant bmp ligands and other approaches targeting Bmpr-Ii in the treatment of pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2015;2015(4):47. https://doi.org/10.5339/Gcsp.2015.47.CrossRefPubMedPubMedCentral

67.

Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira PJ, Badesch DB. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023;61(1):2201347. https://doi.org/10.1183/13993003.01347-2022.CrossRefPubMedPubMedCentral

68.

Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M, STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16):1478–1490. https://doi.org/10.1056/NEJMoa2213558.

69.

Study of sotatercept in newly diagnosed intermediate- and high-risk pah participants (Mk-7962-005/A011-13) (Hyperion). https://Clinicaltrials.Gov/Ct2/Show/Nct04811092. Accessed 09 Jan 2023.

70.

A long-term follow-up study of sotatercept for Pah treatment (Mk-7962-004) (Soteria). https://Clinicaltrials.Gov/Ct2/Show/Nct04796337. Accessed 09 Jan 2023.

71.

A study of sotatercept in participants with Pah who Fc Iii or Fc Iv at high risk of mortality (Mk-7962-006/Zenith) (Zenith). https://Clinicaltrials.Gov/Ct2/Show/Nct04896008. Accessed 09 Jan 2023.

72.

Midgett C, Stitham J, Martin KA, Hwa J. Prostacyclin receptor regulation—from transcription to trafficking. Curr Mol Med. 2011;11(7):517–28. https://doi.org/10.2174/156652411800615144.CrossRefPubMedPubMedCentral

73.

Torres F, et al. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019;54(4).

74.

A study evaluating the efficacy and safety of ralinepag to improve treatment outcomes in PAH patients, NCT03626688. https://clinicaltrials.gov/ct2/show/NCT03626688. Accessed 19 Apr 2023.

75.

A study of ralinepag to evaluate effects on exercise capacity by CPET in subjects with WHO Group 1 PH (CAPACITY), NCT04084678. https://clinicaltrials.gov/ct2/show/NCT04084678. Accessed 19 Apr 2023.

76.

A study evaluating the long-term efficacy and safety of ralinepag in subjects with PAH via an open-label extension. https://clinicaltrials.gov/ct2/show/NCT03683186. Accessed 19 Apr 2023.

77.

LeVarge BL, Channick RN. Inhaled treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Respir Med. 2012;6:255–65. https://doi.org/10.1586/ers.12.23.CrossRefPubMed

78.

Leifer FG, Konicek DM, Chen KJ, et al. Inhaled treprostinil-prodrug lipid nanoparticle formulations provide long-acting pulmonary vasodilation. Drug Res (Stuttg). 2018;68:605–14. https://doi.org/10.1055/s-0044-100374.CrossRefPubMed

79.

Ismat FA, Usansky HH, Villa R, Zou J, Teper A. Safety, tolerability, and pharmacokinetics of treprostinil palmitil inhalation powder for pulmonary hypertension: a phase 1, randomized, double-blind, single- and multiple-dose study. Adv Ther. 2022;39(11):5144–57. https://doi.org/10.1007/s12325-022-02296-x.CrossRefPubMedPubMedCentral

80.

A study of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH)—NCT04791514. https://clinicaltrials.gov/ct2/show/NCT04791514. Accessed 19 Apr 2023.

81.

A study to evaluate the safety and tolerability of treprostinil palmitil inhalation powder in participants with pulmonary hypertension associated with interstitial lung disease—NCT05147805. https://clinicaltrials.gov/ct2/show/NCT05147805. Accessed 19 Apr 2023.

82.

A phase 3 study to evaluate the safety and tolerability of L606 in subjects with Pah. https://Clinicaltrials.Gov/Ct2/Show/Nct04691154?Id=Nct04691154&Draw=2&Rank=1&Load=Cart. Accessed 10 Jan 2023.

83.

Lazarus H, Denning J, Wring S, Palacios M, Hoffman S, Crizer K, Kamau-Kelley W, Symonds W, Feldman J. A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (elevate 2). Pulm Circ. 2022;12(2):E12088. https://doi.org/10.1002/Pul2.12088.CrossRefPubMedPubMedCentral

84.

A study of rodatristat ethyl in patients with pulmonary arterial hypertension (Elevate 2). https://Clinicaltrials.Gov/Ct2/Show/Nct04712669. Accessed 10 Jan 2023.

85.

Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk G-C, Hamilton G, Novotny C, Burian B, Block L-H. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003;111(9):1339–46. https://doi.org/10.1172/Jci17500.CrossRefPubMedPubMedCentral

86.

Phase 2 study to assess safety, tolerability and efficacy of once weekly Sc pemziviptadil (Pb1046) in subjects with symptomatic Pah (Vip). https://Clinicaltrials.Gov/Ct2/Show/Nct03556020. Accessed 10 Jan 2023.

87.

Long-term, open label extension study of pemziviptadil (Pb1046) in Pah subjects following completion of study Pb1046-Pt-Cl-0004 (Vip Extend). https://www.Clinicaltrials.Gov/Ct2/Show/Nct03795428. Accessed 15 Jan 2023.

88.

Bajwa E, Cislak D, Palcza J, Feng HP, Messina E, Reynders T, Denef J, Corcea V, Lai E, Stoch S. Effects of an inhaled soluble guanylate cyclase (Sgc) stimulator Mk-5475 in pulmonary arterial hypertension (Pah). Respir Med. 2023;206: 107065. https://doi.org/10.1016/J.Rmed.2022.107065.CrossRefPubMed

89.

A study of the efficacy and safety of Mk-5475 in participants with pulmonary arterial hypertension (Insignia-Pah: Phase 2/3 study of an inhaled Sgc Stimulator In Pah) (Mk-5475-007). https://Clinicaltrials.Gov/Ct2/Show/Nct04732221. Accessed 15 Jan 2023.

90.

Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1046–51. https://doi.org/10.1038/nbt.1990.CrossRefPubMed

91.

Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811–21. https://doi.org/10.1172/JCI24838.CrossRefPubMedPubMedCentral

92.

Perros F, Montani D, Dorfmüller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:81–8. https://doi.org/10.1164/rccm.200707-1037OC.CrossRefPubMed

93.

Ghofrani HA, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182(9):1171–7.PubMedPubMedCentralCrossRef

94.

Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, Gómez-Sánchez MA, Grimminger F, Grünig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128–38. https://doi.org/10.1161/CIRCULATIONAHA.112.000765.CrossRefPubMed

95.

Positioning imatinib for pulmonary arterial hypertension (Pipah). https://Clinicaltrials.Gov/Ct2/Show/Nct04416750. Accessed 15 Jan 2023.

96.

A study of Av-101 (dry powder inhaled imatinib) in patients with pulmonary arterial hypertension (Pah) (Impahct). https://Clinicaltrials.Gov/Ct2/Show/Nct05036135. Accessed 15 Jan 2023.

97.

Inhaled imatinib pulmonary arterial hypertension clinical trial—follow up long term extension (IMPAHCT-FUL)—NCT05557942. https://clinicaltrials.gov/ct2/show/NCT05557942. Accessed 9 Apr 2023.

98.

Galkin A, Sitapara R, Clemons B, Garcia E, Kennedy M, Guimond D, Carter L, Douthitt A, Osterhout R, Gandjeva A, Slee D, Salter-Cid L, Tuder R, Zisman L. Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. Eur Respir J. 2022;60(6):2102356. https://doi.org/10.1183/13993003.02356-2021.CrossRefPubMedPubMedCentral

99.

Li J, Yamashita M, Cravets M, et al. Phase 1A randomized double-blind placebo-controlled single-ascending dose and multiple-ascending dose studies of orally inhaled GB002 in healthy adult subjects. Am J Respir Crit Care Med. 2020;201:A2907.

100.

Open-label extension study of Gb002 in adult subjects with pulmonary arterial hypertension (Pah). https://Clinicaltrials.Gov/Ct2/Show/Nct04816604. Accessed 16 Jan 2023.

101.

Mair K, Wright A, Duggan N, Rowlands D, Hussey M, Roberts S, Fullerton J, Nilsen M, Loughlin L, Thomas M, Maclean M. Sex-dependent influence of endogenous estrogen in pulmonary hypertension. Am J Respir Crit Care Med. 2014;190(4):456–67. https://doi.org/10.1164/Rccm.201403-0483oc.CrossRefPubMedPubMedCentral

102.

Tamoxifen therapy to treat pulmonary arterial hypertension (T3pah). https://Clinicaltrials.Gov/Ct2/Show/Nct03528902. Accessed 16 Jan 2023.

103.

Wang Z, Jiang X, Zhang X, Tian G, Yang R, Wu J, Zou X, Liu Z, Yang X, Wu C, Shi J, Li J, Suo J, Wang Y, Zhang R, Xu Z, Gong X, He Y, Zhu W, Aisa H, Jiang H, Xu Y, Shen J. Pharmacokinetics-driven optimization of 4(3 H)-pyrimidinones as phosphodiesterase type 5 inhibitors leading to Tpn171, a clinical candidate for the treatment of pulmonary arterial hypertension. J Med Chem. 2019;62(10):4979–90. https://doi.org/10.1021/Acs.Jmedchem.9b00123.CrossRefPubMed

104.

Acute haemodynamic study of Tpn171h in patients with pulmonary arterial hypertension. https://Clinicaltrials.Gov/Ct2/Show/Nct04483115. Accessed 20 Jan 2023.

105.

Jing Z, Yu Z, Shen J, Wu B, Xu K, Zhu X, Pan L, Zhang Z, Liu X, Zhang Y, Jiang X, Galiè N. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183(12):1723–9. https://doi.org/10.1164/Rccm.201101-0093oc.CrossRefPubMed

106.

Eldon MA, Parsley EL, Maurer M, Tarara TE, Okikawa J, Weers JG. Safety, tolerability, and pharmacokinetics of RT234 (vardenafil inhalation powder): a first-in-human, ascending single- and multiple-dose study in healthy subjects. J Aerosol Med Pulm Drug Deliv. 2021;34:251–61. https://doi.org/10.1089/jamp.2020.1651.CrossRefPubMedPubMedCentral

107.

Vardenafil inhaled for pulmonary arterial hypertension Prn phase 2b study (Vipah-Prn 2b). https://Clinicaltrials.Gov/Ct2/Show/Nct04266197. Accessed 20 Jan 2023.

108.

Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007;76:75–100.PubMedCrossRef

109.

Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol. 2009;297:F729–39.PubMedCrossRef

110.

Harrison IF, Dexter DT. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson’s disease. Pharmacol Ther. 2013;140:34–52.PubMedCrossRef

111.

Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation. 2012;126(4):455–67. https://doi.org/10.1161/CIRCULATIONAHA.112.103176.CrossRefPubMedPubMedCentral

112.

Cho YK, Eom GH, Kee HJ, Kim HS, Choi WY, Nam KI, Ma JS, Kook H. Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J. 2010;74(4):760–70. https://doi.org/10.1253/circj.CJ-09-0580.CrossRefPubMed

113.

Cereno. 2022. https://Cerenoscientific.Com/Pipeline/Cs1/.

114.

Effect of Cs1 in subjects with pulmonary arterial hypertension. https://Clinicaltrials.Gov/Ct2/Show/Nct05224531. Accessed 20 Jan 2023.

115.

Fric J, Zelante T, Wong AY, Mertes A, Yu HB, Ricciardi-Castagnoli P. NFAT control of innate immunity. Blood. 2012;120:1380–9. https://doi.org/10.1182/blood2012-02-404475.CrossRefPubMed

116.

Satralizumab in the treatment of pulmonary arterial hypertension (SATISFY-JP Trial), NCT05679570. https://clinicaltrials.gov/ct2/show/NCT05679570. Accessed 9 April 2023.

117.

https://synapse.patsnap.com/drug/04efca99118e43d8adc38cd21d9c28ef.

118.

Murakami K, Mathew R, Huang J, Farahani R, Peng H, Olson SC, Etlinger JD. Smurf1 ubiquitin ligase causes downregulation of BMP receptors and is induced in monocrotaline and hypoxia models of pulmonary arterial hypertension. Exp Biol Med (Maywood). 2010;235(7):805–13. https://doi.org/10.1258/ebm.2010.009383.CrossRefPubMed

119.

Study of efficacy and safety of LTP001 in pulmonary arterial hypertension, NCT05135000. https://clinicaltrials.gov/ct2/show/NCT05135000. Accessed 10 Apr 2023.

Title: Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications
Authors: Maria Eugenia Novara
Enrica Di Martino
Brandon Stephens
Mary Nayrouz
Patrizio Vitulo
Anna Carollo
Alessio Provenzani
Publication date: 22-03-2024
Publisher: Springer International Publishing
Keywords: Arterial Hypertension
Arterial Hypertension
Vardenafil
Published in: Drugs in R&D / Issue 1/2024
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI: https://doi.org/10.1007/s40268-024-00453-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Real-World Experience of Carglumic Acid for Methylmalonic and Propionic Acidurias: An Interim Analysis of the Multicentre Observational PROTECT Study

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

Bioequivalence Study of Tebipenem Pivoxil in Healthy Chinese Adults

Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects

Unveiling the Influence of a High-Fat Meal on the Pharmacokinetics of Oral Globalagliatin, A Glucokinase Activator, in Healthy Chinese Volunteers

Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice